Salix shares surge after FDA grants priority review to use of irritable bowel drugInformation on Salix shares surge after FDA grants priority review to use of irritable bowel drug under Irritable Bowel Syndrome section of the Health Articles & Reviews; RALEIGH, N.C. Shares in Salix Pharmaceuticals (Nasdaq: SLXP ) surged more than 3 percent, or $1.37 per share, Monday on news that the Food and ... |
 |
|
Salix shares surge after FDA grants priority review to use of irritable bowel drug
by Anthony F Boyle 08-12-2010, 07:53 PM
RALEIGH, N.C. Shares in Salix Pharmaceuticals (Nasdaq: SLXP ) surged more than 3 percent, or $1.37 per share, Monday on news that the Food and Drug Administration has granted a priority review for use of a Salix product.
More... |
Views 22
Comments 0
|
|
| Bookmarks |
| Currently Active Users Viewing This Article: 1 (0 members and 1 guests) | |
| Article Tools | |
| Display Modes | |
|
|
 |  |  |  |
 |  |  |  |
 |  |  |  |
 |  |  |  |
 |  |  |  |
Linear Mode
